Socrates Said," Let foods be your medicine and let medicine be your foods". Let us all practice the values of the past wisdom to build a letter living and living health while we enjoy the delicious drinks

Tuesday, August 29, 2017

All About Vitamins: Vitamin B3 in Reduced Risk of Hyperlipidemia

Kyle J. Norton(Scholar, Master of Nutrients), all right reserved.
Health article writer and researcher; Over 10.000 articles and research papers have been written and published on line, including world wide health, ezine articles, article base, healthblogs, selfgrowth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bio science, ISSN 0975-6299.

Niacin, is also known as vitamin B3, nicotinic acid, an organic compound with the formula
C6H5NO2, found abundantly in chicken, beef, fish, cereal, peanuts and legumes. The Vitamin is best known for its effects in lowering cholesterol and triglycerides and removing toxic from our body and promoting production of steroid hormones.

Hyperlipidemia is a condition of abnormal high blood cholesterol and triglycerides.

Vitamin B3 and its derivative may be next potential micro nutrient in reduced risk and treatment of high blood cholesterol. a respectable institute postulated.

According to the Institute of Macromolecular Chemistry, vitamin B3 showed a impressive activity in reduced risk and decreased levels of cholesterol and triglycerides in a range of 14 to 16 mg daily in adults and from 1 to 3 g, respectively.

The examined content of niacin(NA) in tablets between 65-80 %, under three different pH values (1, 4.5 and 6.8) over the time period of 30 h, also suggested that the efficacy of niacin released in the gastrointestinal environment can be increased, depending to the adjustment to specific medical requirements.

In compared the efficacy and safety of ERN/LRPT plus simvastatin (ERN/LRPT+SIMVA) with atorvastatin (ATORVA)  in mixed hyperlipidemia of 2340 patients (LDL-C ≥ 130 and ≤ 190 mg/dL, TG ≥ 150 and ≤ 500 mg/dL and above NCEP ATP III risk-based LDL-C goal), ERN/LRPT treatment group showed a superior in improved lipid parameters after 12 weeks with well tolerated adverse effect in comparison to other groups.

Dr. Vogt A in the differentiation of effects of niacin against hyperlipoproteinaemia, said," All lipid lowering medications in use mainly lower low density lipoprotein-cholesterol (LDL-c) with no or limited effect on levels of Lp(a). Niacin, the only component lowering Lp(a), is firstly often poorly tolerated and secondly not available anymore in many countries. A level of <50 mg/dl was recommended recently as the cut off level for clinical use and decision making".

The finding evidences indicated that vitamin B3  may be a potential natural therapeutic micro nutrient in reduced risk and treatment of high blood cholesterol and triglycerides without induced adverse effects

FOOD HACK for Weight Loss
A Simple Cooking Technique That Cuts The Calories & Glycemic 
Impact In Rice, Pasta, And Potatoes In Half

Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months

FOOD HACK for Weight Loss
A Simple Cooking Technique That Cuts The Calories & Glycemic 
Impact In Rice, Pasta, And Potatoes In Half

(1) The use of a hydrogel matrix for controlled delivery of niacin to the gastrointestinal tract for treatment of hyperlipidemia by Sirc J1, Hrib J, Vetrik M, Hobzova R, Zak A, Stankova B, Slanar O, Hromadka R, Sandrikova V, Michalek J.(PubMed)
(2) Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia by Chen F1, Maccubbin D, Yan L, Sirah W, Chen E, Sisk CM, Davidson M, Blomqvist P, McKenney JM.(PubMed)
(3) Hyperlipoproteinaemia(a) - apheresis and emerging therapies by Vogt A1.(PubMed)

No comments:

Post a Comment